Business Wire – International World Of Business

REMINDER: Beyond Meat, Inc. Investors With Significant Losses Must Act By March 24, 2026

Press Room Team — Sat, 21 Feb 2026 04:55:02 +0000

NEW YORK–(BUSINESS WIRE)–Kirby McInerney LLP reminds Beyond Meat, Inc. (“Beyond Meat” or the “Company”) (NASDAQ:BYND) investors of the March 24, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.

If you purchased or otherwise acquired Beyond Meat securities, have information, or would like to learn more, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the form below, to discuss your rights or interests.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of February 27, 2025 through November 11, 2025, inclusive (“the Class Period”). The lawsuit alleges that (i) the book value of long-lived assets exceeded their fair value, making it highly likely that the Company would be required to record a material, non-cash impairment charge; (ii) the foregoing was likely to impair Beyond Meat’s ability to timely file its periodic filings with the U.S. Securities and Exchange Commission.

On October 24, 2025, Beyond Meat reported preliminary financial results for the third quarter of 2025 (“Q3 2025”). Therein, the Company announced that it “expects to record a non-cash impairment charge for the three months ended September 27, 2025, related to certain of its long-lived assets,” which it “expected to be material.” On this news, Beyond Meat shares declined by $0.65 per share, or approximately 22.89%, to close at $2.19 on October 24, 2025.

Then, on November 3, 2025, the Company delayed its earnings announcement for 3Q 25, citing the need for more time to complete its impairment review. On this news, Beyond Meat shares declined by $0.27 per share, or approximately 16.27%, to close at $1.39 on November 3, 2025.

On November 10, 2025, Beyond Meat announced financial results for 3Q 2025, reporting a loss from operations for the quarter of $112.3 million, which included a $77.4 million non-cash impairment charge “related to certain of the Company’s long-lived assets.” On this news, Beyond Meat shares declined by $0.12 per share, or approximately 8.96%, to close at $1.22 on November 11, 2025.

Finally, on November 11, 2025, Beyond Meat disclosed on its 3Q 2025 earnings call with investors and analysts that “[t]he total impairment amount of $77.4 million was . . . allocated to PP&E, operating lease ROU assets and prepaid lease costs on our balance sheet.” On this news, Beyond Meat’s shares fell an additional $0.11 per share, or approximately 8.61%, to close at $1.12 per share on November 12, 2025.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Beyond Meat securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP

Lauren Molinaro, Esq.

212-699-1171

https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit

Press Room Team — Sat, 21 Feb 2026 04:55:02 +0000

SAN DIEGO–(BUSINESS WIRE)–$CORT #Health—Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Corcept Therapeutics Incorporated (CORT) Misled Investors Regarding the Viability of its New Product Candidate

According to the complaint, one of Corcept’s lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as “Cushing’s syndrome”). During the class period, defendants represented that the key clinical trials supporting the use of relacorilant as treatment for patients with hypercortisolism were “powerful support” for the New Drug Application (“NDA”) that Corcept submitted to the U.S. Food and Drug Administration (“FDA”) for this indication. Defendants also stated that they had communicated with the FDA about this NDA and were confident in submitting the NDA, foreseeing no impediments to approval. Toward the latter part of the class period, Defendants repeatedly told investors that “relacorilant is approaching approval.”

Plaintiff alleges that in truth, the FDA had raised concerns about the adequacy of the clinical evidence supporting the NDA and, as a result there was a known material risk that Corcept’s relacorilant NDA would not be approved.

The complaint continues that on December 31, 2025, Corcept revealed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.” As a result of this disclosure, the price of Corcept common stock declined from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025, or 50.4%.

What Now: You may be eligible to participate in the class action against Corcept Therapeutics Incorporated. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Corcept Therapeutics Incorporated settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.

Robbins LLP

5060 Shoreham Pl., Ste. 300

San Diego, CA 92122

adumas@robbinsllp.com
(800) 350-6003

www.robbinsllp.com

Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Corcept Therapeutics Incorporated

Press Room Team — Sat, 21 Feb 2026 04:55:02 +0000

NEW YORK–(BUSINESS WIRE)–Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) filed a class action lawsuit in the U.S. District Court for the Northern District of California alleging violations of the federal securities laws by Corcept Therapeutics Incorporated (“Corcept” or the “Company”) and certain of the Company’s current senior executives (collectively, “Defendants”). The action is brought on behalf of all investors who purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”).

The case is captioned Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 (N.D. Cal.). The complaint is based on an extensive investigation and a careful evaluation of the merits of this case. A copy of the complaint is available on BLB&G’s website by clicking here.

Corcept’s Alleged Fraud

Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. One of its lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as “Cushing’s syndrome”).

The complaint alleges that, throughout the Class Period, Defendants represented that the key clinical trials supporting the use of relacorilant as treatment for patients with hypercortisolism were “powerful support” for the New Drug Application (“NDA”) that Corcept submitted to the U.S. Food and Drug Administration (“FDA”) for this indication. Defendants also stated that they had communicated with the FDA about this NDA and were confident in submitting the NDA, foreseeing no impediments to approval. Toward the latter part of the Class Period, Defendants repeatedly told investors that “relacorilant is approaching approval.” In truth, the FDA had repeatedly raised concerns about the adequacy of the clinical evidence supporting the relacorilant NDA and, as a result, there was a known material risk that Corcept’s relacorilant NDA would not be approved.

The truth emerged on December 31, 2025, when Corcept revealed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.” As a result of this disclosure, the price of Corcept common stock declined by $35.40 per share, or 50.4%.

On January 30, 2026, after the end of the Class Period, the FDA published a redacted copy of the CRL. The CRL detailed the FDA’s concerns with the relacorilant NDA, including concerns that the clinical studies that were submitted as part of the NDA were not sufficient evidence of relacorilant’s efficacy for the proposed indication. The CRL also noted that, during pre-submission meetings, the FDA informed Corcept “on several occasions” of its “concerns about the adequacy of the clinical development program,” and had warned the Company “to expect significant review issues,” if it submitted the application.

If you wish to serve as Lead Plaintiff for the Class, you must file a motion with the Court no later than April 21, 2026, which is the first business day on which the U.S. District Court for the Northern District of California is open that is 60 days after the publication date of February 20, 2026. Any member of the proposed Class may seek to serve as Lead Plaintiff through counsel of their choice, or may choose to do nothing and remain a member of the proposed Class.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Scott R. Foglietta of BLB&G at 212-554-1903, or via e-mail at scott.foglietta@blbglaw.com.

About BLB&G

BLB&G is widely recognized worldwide as a leading law firm advising institutional investors on issues related to corporate governance, shareholder rights, and securities litigation. Since its founding in 1983, BLB&G has built an international reputation for excellence and integrity and pioneered the use of the litigation process to achieve precedent-setting governance reforms. Unique among its peers, BLB&G has obtained several of the largest and most significant securities recoveries in history, recovering over $40 billion on behalf of defrauded investors. More information about the firm can be found online at www.blbglaw.com.

Contacts

Scott R. Foglietta

Bernstein Litowitz Berger & Grossmann LLP

1251 Avenue of the Americas, 44th Floor

New York, New York 10020

(212) 554-1903

scott.foglietta@blbglaw.com

The Cannabist Company Further Extends Forbearance Agreement With Senior Noteholders

Press Room Team — Sat, 21 Feb 2026 04:55:02 +0000

CHELMSFORD, Mass.–(BUSINESS WIRE)–The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) (“The Cannabist Company” or the “Company”), one of the most experienced cultivators, manufacturers, and retailers of cannabis products in the United States, today announced that the ad hoc group of noteholders of the Company’s 9.25% Senior Secured Notes due December 31, 2028 and the 9.00% Senior Secured Convertible Notes due December 31, 2028 (collectively, the “Notes”), which are parties to the previously announced forbearance agreement with the Company, have agreed to a further extension and to forbear from exercising any of their rights and remedies under the amended and restated indenture, as supplemented, governing the Notes and applicable law, until February 27, 2026.

About The Cannabist Company (f/k/a Columbia Care)

The Cannabist Company, formerly known as Columbia Care, is one of the most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 11 U.S. jurisdictions. The Company operates 69 facilities including 54 dispensaries and 15 cultivation and manufacturing facilities, including those under development. Columbia Care, now The Cannabist Company, is one of the original multi-state providers of cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the Company launched Cannabist, its retail brand, creating a national dispensary network that leverages proprietary technology platforms. The Company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including dreamt, Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber. For more information, please visit www.cannabistcompany.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 and corresponding Canadian securities laws. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding use of proceeds, future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, as well as the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2024, its quarterly report on Form 10-Q for the quarter ended September 30, 2025, and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov and in Canada on SEDAR+, available at www.sedarplus.ca. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Contacts

Investor & Media Contact
Lee Ann Evans

SVP, Capital Markets & Communications

investor@cannabistcompany.com

DXP Enterprises, Inc. Announces Fourth Quarter and Fiscal 2025 Earnings Release and Conference Call

Press Room Team — Sat, 21 Feb 2026 04:55:01 +0000

HOUSTON–(BUSINESS WIRE)–#DXPE—DXP Enterprises, Inc. (the “Company”) (NASDAQ: DXPE), a leading business to business products and service distributor that adds value and total cost savings solutions to MRO and OEM customers in virtually every industry, plans to issue a press release announcing its financial results for the fourth quarter and Fiscal Year ended December 31, 2025, on Wednesday, February 25^th. The earnings announcement will be released after the market closes. DXP will host a conference call, to be web cast live, on the Company’s website (www.dxpe.com) at 10:30 AM Central Time on Thursday, February 26^th.

The call and an accompanying slide presentation will be on the “Investor Relations” section of DXP’s website at www.dxpe.com. A replay of the webcast will be available shortly after the conclusion of the presentation.

DXP’s earnings press release, the slides and other related presentation materials will be posted to the “Investor Relations” section of DXP’s website under the subheading “Financial Information” after the market closes on the date of the earnings call and will remain available following the call.

Web participants are encouraged to go to the Company’s website (www.dxpe.com) at least 15 minutes prior to the start of the call to register, download and install any necessary audio software.

The Private Securities Litigation Reform Act of 1995 provides a “safe-harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made by or to be made by the Company) contains statements that are forward-looking. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future; and accordingly, such results may differ from those expressed in any forward-looking statement made by or on behalf of the Company. These risks and uncertainties include, but are not limited to; ability to obtain needed capital, dependence on existing management, leverage and debt service, domestic or global economic conditions, and changes in customer preferences and attitudes. For more information, review the Company’s filings with the Securities and Exchange Commission.

Contacts

DXP Enterprises, Inc.

Kent Yee, 713-996-4700

Senior Vice President, CFO

www.dxpe.com

KBRA Assigns Preliminary Ratings to Angel Oak Mortgage Trust 2026-2 (AOMT 2026-2)

Press Room Team — Sat, 21 Feb 2026 04:55:01 +0000

NEW YORK–(BUSINESS WIRE)–#creditratingagency–KBRA assigns preliminary ratings to ten classes of mortgage-backed certificates from Angel Oak Mortgage Trust 2026-2 (AOMT 2026-2), a $272.8 million non-prime RMBS transaction. The underlying collateral, comprised of 585 residential mortgages, is characterized by a significant concentration of loans underwritten using alternative income documentation. All the loans are either classified as non-qualified mortgages (Non-QM) (52.1%) or exempt (47.9%) from the Ability-to-Repay/Qualified Mortgage (ATR/QM) rule due to being originated for non-consumer loan purposes. Angel Oak Mortgage Solutions and Emporium TPO are the largest originators, comprising 24.8% and 10.1% of the pool respectively, with no other originator comprising more than 10% of the collateral.

KBRA’s rating approach incorporated loan-level analysis of the mortgage pool through its Residential Asset Loss Model (REALM), an examination of the results from third-party loan file due diligence, cash flow modeling analysis of the transaction’s payment structure, reviews of key transaction parties and an assessment of the transaction’s legal structure and documentation. This analysis is further described in our U.S. RMBS Rating Methodology.

To access ratings and relevant documents, click here.

Click here to view the report.

Related Publications

Methodologies

Disclosures

Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above.

A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here.

Information on the meaning of each rating category can be located here.

Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at www.kbra.com.

About KBRA

Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan’s Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S.

Doc ID: 1013592

Contacts

Analytical Contacts

Edward DeVito, Senior Managing Director (Lead Analyst)

+1 646-731-2319

edward.devito@kbra.com

Liam Vauk, Associate

+1 646-731-1323

liam.vauk@kbra.com

Patrick Gervais, Senior Managing Director (Rating Committee Chair)

+1 646-731-2426

patrick.gervais@kbra.com

Business Development Contact

Daniel Stallone, Managing Director

+1 646-731-1308

daniel.stallone@kbra.com

Federal Transportation Board Preserves Fort Bragg–Willits Rail Line; Mendocino Railway Calls for Collaborative Rail-and-Trail Future

Press Room Team — Sat, 21 Feb 2026 04:55:01 +0000

WILLITS, Calif.–(BUSINESS WIRE)–The Surface Transportation Board yesterday denied a request to remove the 40-mile Fort Bragg–Willits rail corridor from the national rail network, preserving the line for continued freight and passenger use.

The unanimous decision confirms that the corridor remains part of the interstate rail system and recognizes its potential for present and future rail service.

“This corridor remains a vital public asset for Mendocino County,” said Robert Jason Pinoli, President and CEO of Mendocino Railway. “We appreciate the Board’s thoughtful review. Our focus now is simple: protect the corridor, continue investing in it, and work constructively with regional partners on long-term solutions.”

A Path Forward: Rail and Trail

The Board’s decision does not prevent trail development. Instead, it makes clear that recreational trail use can coexist with rail service where properly planned.

Mendocino Railway is calling for renewed collaboration with the Great Redwood Trail Agency to pursue a coordinated rail-and-trail approach that serves both transportation and recreation goals.

“We respect the GRTA’s vision,” Pinoli said. “Rail corridors are uniquely valuable because they can serve multiple public purposes. We are prepared to work together on a solution that preserves freight access, maintains passenger service, and expands trail opportunities for the community.”

Mendocino Railway has extensive experience developing and maintaining rail-with-trail projects in California and owns the specialized equipment required to build and steward trail infrastructure responsibly.

Continued Investment in the Corridor

The company is actively advancing federally supported infrastructure improvements designed to restore full functionality of the line between Fort Bragg and Willits. These investments are intended to strengthen freight options for local businesses, preserve tourism through excursion passenger service, and maintain long-term transportation flexibility in a rural region with limited alternatives.

“This is about keeping options open for future generations,” Pinoli said. “Once a rail corridor is lost, it is rarely recovered. Our commitment is to protect it, and to ensure it serves the people and businesses of Mendocino County in the most constructive way possible.”

About Mendocino Railway

Mendocino Railway is a federally regulated Class III common carrier public utility railroad providing freight and passenger service in Northern California. Since 2004, the company has operated and maintained the historic Fort Bragg–Willits line, including the Skunk Train passenger service. The company remains committed to safe operations, infrastructure investment, and community partnership. For more information, visit www.mendocinorailway.com.

Contacts

For more information or media inquiries, please contact:

Kimberly Preciado

Public Relations Manager

Mendocino Railway

kpreciado@sierrarailroad.com

SmartStop Self Storage REIT Announces Appointment of New Management Board Member

Press Room Team — Sat, 21 Feb 2026 04:55:00 +0000

LADERA RANCH, Calif.–(BUSINESS WIRE)–SmartStop Self Storage REIT, Inc. (“SmartStop”) (NYSE: SMA), an internally managed real estate investment trust and a premier owner and operator of self-storage facilities in the United States and Canada, today announced the appointment of Wayne Johnson to its Board of Directors. Mr. Johnson currently serves as SmartStop’s Chief Investment Officer.

“Wayne’s deep industry expertise and decades of leadership in the self-storage and commercial real estate sectors make him an exceptional addition to our Board of Directors,” said H. Michael Schwartz, Chairman and CEO of SmartStop. “His strategic vision has played a pivotal role in our growth, and we are fortunate to continue benefiting from his insight at the board level. We look forward to his guidance as we advance our long-term strategy and pursue new opportunities for the company.”

Mr. Johnson has served as Chief Investment Officer since 2015. He also served as President from 2019 until his appointment to the Board. He has been a key leader in the company’s growth since its formation in 2013, previously serving as Senior Vice President of Acquisitions with a focus on self-storage investments. His career includes senior leadership roles across multiple affiliated real estate platforms, including Chief Investment Officer roles for all of SmartStop’s Managed REITs, as well as real estate programs previously sponsored by SmartStop’s former sponsor.

Prior to his career with SmartStop and its affiliates, Mr. Johnson worked extensively in commercial real estate development and leasing, managing projects spanning office, warehouse, retail, and self-storage facilities. He has developed, managed, and operated more than one million square feet of self-storage properties.

A recognized industry leader, Mr. Johnson currently serves on the board of directors of the Self Storage Association’s Large Operator Council and was a past President and board member of the Texas Self Storage Association. He began his real estate career in 1979 after earning a B.B.A. in finance and real estate from Southern Methodist University.

About SmartStop Self Storage REIT, Inc. (SmartStop):

SmartStop Self Storage REIT, Inc. (“SmartStop”) (NYSE: SMA) is a self-managed REIT with a fully integrated operations team of more than 1,000 self-storage professionals focused on growing the SmartStop® Self Storage brand. SmartStop, through its indirect subsidiary, SmartStop REIT Advisors, LLC, also sponsors other self-storage programs and, through its Managed Platform, offers third-party management services in the U.S. and Canada. As of February 20, 2026, SmartStop has an owned or managed portfolio of over 460 operating properties in 35 states, the District of Columbia, and Canada, comprising over 270,000 units and more than 35 million rentable square feet. SmartStop and its affiliates own or manage 49 operating self-storage properties across four provinces in Canada, which total approximately 42,200 units and 4.3 million rentable square feet. Additional information regarding SmartStop is available at www.smartstopselfstorage.com.

Contacts

Investor Relations Contact:
David Corak

Senior VP of Corporate Finance and Strategy

SmartStop Self Storage REIT, Inc.

IR@smartstop.com

Media Relations Contact:
Spotlight Marketing Communications

949-427-5172

info@spotlightmc.com

KBRA Assigns Preliminary Ratings to Aspire Mortgage Trust 2026-1 (SPIRE 2026-1)

Press Room Team — Sat, 21 Feb 2026 04:55:00 +0000

NEW YORK–(BUSINESS WIRE)–#creditratingagency–KBRA assigns preliminary ratings to eight classes of mortgage-backed notes from Aspire Mortgage Trust 2026-1 (SPIRE 2026-1), a $391.3 million non-prime RMBS transaction. The underlying collateral, comprising 752 residential mortgages, is characterized by fixed-rate mortgages (FRMs) and hybrid adjustable-rate mortgages (ARMs), which make up 99.2% and 0.8% of the pool, respectively. The loans are classified as Qualified Mortgages – Safe Harbor (APOR) (QM: Safe Harbor (APOR)) (27.3%), Qualified Mortgages – Rebuttable Presumption (APOR) (QM: Rebuttable Presumption (APOR)) (3.4%), Non-Qualified Mortgages (Non-QM) (16.8%), or exempt (52.5%) from the Ability-to-Repay/Qualified Mortgage (ATR/QM) rule due to origination for non-consumer loan purposes.

To access ratings and relevant documents, click here.

Click here to view the report.

Related Publications

Methodologies

Disclosures

Information on the meaning of each rating category can be located here.

About KBRA

Doc ID: 1013564

Contacts

Analytical Contacts

Minxi Qiu, Director (Lead Analyst)

+1 646-731-1263

minxi.qiu@kbra.com

Tom Reilly, Director

+1 646-731-2317

tom.reilly@kbra.com

Patrick Gervais, Senior Managing Director (Rating Committee Chair)

+1 646-731-2426

patrick.gervais@kbra.com

Business Development Contact

Daniel Stallone, Managing Director

+1 646-731-1308

daniel.stallone@kbra.com

Rosen Law Firm Encourages DNOW Inc. Investors to Inquire About Securities Class Action Investigation – DNOW

Press Room Team — Sat, 21 Feb 2026 04:55:00 +0000

NEW YORK–(BUSINESS WIRE)–Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of DNOW Inc. (NYSE: DNOW) resulting from allegations that DNOW Inc. may have issued materially misleading business information to the investing public.

So What: If you purchased DNOW Inc. securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=53946 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

What is this about: On February 20, 2026, StockStory published an article entitled “Why DNOW (DNOW) Shares Are Getting Obliterated Today.” The article stated that DNOW shares fell “after the company reported disappointing fourth-quarter 2025 financial results, which included a significant loss and missed Wall Street’s expectations.”

On this news, DNOW stock fell 19.1% on February 20, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

case@rosenlegal.com
www.rosenlegal.com